Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
02/24/2020 02/25/2020 02/26/2020 02/27/2020 02/28/2020 Date
118(c) 116.15(c) 115.9(c) 112.9(c) 109.05 Last
915 368 837 744 844 016 960 231 1 316 321 Volume
-4.88% -1.57% -0.22% -2.59% -3.41% Change
More quotes
Financials (EUR)
Sales 2019 16 092 M
EBIT 2019 2 262 M
Net income 2019 1 448 M
Debt 2019 10 271 M
Yield 2019 1,22%
Sales 2020 17 562 M
EBIT 2020 2 819 M
Net income 2020 1 924 M
Debt 2020 8 559 M
Yield 2020 1,31%
P/E ratio 2019 32,5x
P/E ratio 2020 24,5x
EV / Sales2019 3,58x
EV / Sales2020 3,19x
Capitalization 47 413 M
More Financials
Company
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - pharmaceutical products (42.1%): prescribed medicines (treatment of diabetes, cardiovascular diseases, central nervous system disorders and hormonal disorders),... 
Sector
Pharmaceuticals
Calendar
03/03Presentation
More about the company
Surperformance© ratings of Merck KGaA
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK KGAA
02/27Pfizer warns of hit to financial results on continued coronavirus outbreak
RE
02/27Pfizer warns of hit to financial results on continued coronavirus outbreak
RE
02/21Marriott Hires Former Merck CIO as Tech Chief
DJ
02/20EXCLUSIVE : Canadian regulator considers changes to new drug pricing plan
RE
02/20EVOBRUTINIB (RMS) UPDATE CALL - WEBC : 00 cet
PU
02/19MERCK : Darmstadt, Germany, Divests Allergopharma to Dermapharm Holding SE
PU
02/19Merck KGaA sells allergy unit to Dermapharm, keeps autoinjector project
RE
02/19Merck KGaA Sells Allergy Business to Dermapharm
DJ
02/19Immutep Says Interim Phase II TACTI-002 Data Positive
DJ
02/18Marriott Names Jim Scholefield Chief Information, Digital Officer
DJ
02/18Merck KGaA Chosen to Produce Liquid Biopsy Kits
DJ
02/14Merck's Zaire Ebolavirus Vaccine Registered in Four African Countries
DJ
02/13Bayer Seeks to Settle Cases, Keep Roundup -- WSJ
DJ
02/12Bayer Strives to End Lawsuits Over Roundup -- While Still Selling It
DJ
02/12MERCK : Keytruda Combo Meets Main Endpoint in Metastatic Triple-Negative Breast ..
DJ
More news
News in other languages on MERCK KGAA
08:54aWOCHENAUSBLICK : Dax-Anleger hoffen nach Coronavirus-Crash auf leichte Beruhigun..
12:06aWOCHENVORSCHAU : Termine bis 13. März 2020
02/27Agenda economique monde jusqu'au 6 mars
02/26WOCHENVORSCHAU : Termine bis 12. März 2020
02/25WALL STREET STOCK EXCHANGE : Virus-Angst setzt Börsen erneut zu - Dax unter 13.0..
More news
Analyst Recommendations on MERCK KGAA
More recommendations
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 112,05  €
Last Close Price 109,05  €
Spread / Highest target 36,5%
Spread / Average Target 2,75%
Spread / Lowest Target -16,6%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Member-Supervisory Board
Michael Fletterich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA3.51%53 876
KYOWA KIRIN CO., LTD.-0.53%12 713
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD12.04%10 480
JAZZ PHARMACEUTICALS PLC-24.24%6 349
BETTA PHARMACEUTICALS CO., LTD.4.82%4 814
YUHAN CORPORATION0.93%2 187